The Italian company operates over 9,000 clinics across 26 countries, making it the world's largest hearing care retailer. Vita has driven dozens of acquisitions since 2018, but regulators fear a vertically integrated operator could control both supply chains and consumer access points, raising pricing power and competitor exclusion risks.
Healthcare merger reviews in Europe have averaged 6-12 months, with remedy packages required in over 40% of approved deals. EU and US health regulators have previously blocked healthcare consolidations when vertical integration threatened to foreclose competition. Cross-border transactions face multiple review processes, each with authority to impose conditions or prohibit completion.
If manufacturers control retail distribution, independent audiologists lose access to competitive wholesale channels. Market concentration risk increases as aging demographics drive steady demand growth across developed economies. Private equity-backed hearing care consolidators continue acquiring assets in Europe, North America, and Asia-Pacific markets, intensifying competitive pressure.
Financial implications are substantial. Divesting clinics or distribution assets in overlapping markets reduces synergy value and integration benefits. Blocked transactions waste deal costs and management focus while ceding market share gains to competitors. Regulatory intervention likelihood increases with deal size and geographic overlap.
Amplifon must balance growth momentum against regulatory constraints across fragmented jurisdictions. Whether global hearing care consolidation can clear antitrust hurdles or remains fragmented across regional markets will depend on Vita's ability to structure deals that satisfy competition authorities in multiple countries simultaneously.
